Association of Social Vulnerability Index and Chimeric Antigen Receptor T-Cell Therapy Administration, 2018-2023
Open Access
- 24 July 2025
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (9)
Abstract
Chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory hematologic malignancies demands numerous visits which may pose challenges for patients with lower socioeconomic status (SES). The Centers for Disease Control and Prevention publishes the Social Vulnerability Index (SVI) which summarizes area-level SES factors that predict how residents respond to stressors, including a new cancer diagnosis. We used the nationwide MarketScan commercial and Medicare insurance claims database to analyze the association between SVI and CAR T therapy completion. We performed multivariable logistic regressions (adjusting for patient-level covariates) and found that patients with hematologic malignancies residing in areas of higher SVI (lower SES) have decreased odds of CAR T therapy completion (OR 0.84 for leukemia, P = 0.02; OR 0.72 for lymphoma, P < 0.001; OR 0.70 for myeloma, P < 0.001). Therefore, strategies to mitigate CAR T disparities may be focused on patients living in areas with higher SVI.Keywords
This publication has 7 references indexed in Scilit:
- Sex Differences in Outcomes of Chimeric Antigen Receptor (CAR) T‐Cell TherapyCancer Medicine, 2025
- Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapyBlood Advances, 2024
- Barriers to accessing cellular therapy for patients receiving care in community practicesHematology-American Society Hematology Education Program, 2023
- The social vulnerability index as a risk stratification tool for health disparity research in cancer patients: a scoping reviewCancer Causes & Control, 2023
- Demographic differences among patients treated with chimeric antigen receptor T‐cell therapy in the United StatesCancer Medicine, 2022
- Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy AccessTransplantation and Cellular Therapy, 2022
- A Modification of the Elixhauser Comorbidity Measures Into a Point System for Hospital Death Using Administrative DataMedical Care, 2009